查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1986641

CAR-T細胞療法市場規模、佔有率和趨勢分析報告：按產品、疾病、應用、地區和細分市場預測（2026-2033年）

CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

CAR-T細胞療法市場概述

全球 CAR-T 細胞療法市場預計到 2025 年將價值 58.2 億美元，預計到 2033 年將達到 223.6 億美元。

預計從 2026 年到 2033 年，該市場將以 18.06% 的複合年成長率成長。推動市場成長的因素包括癌症患者數量的增加、個人化細胞療法的普及、基因編輯技術的進步以及支持性法規。

癌症負擔加重

癌症，尤其是白血病、淋巴瘤和多發性骨髓瘤等血液癌症的日益流行，正在推動CAR-T細胞療法產業的發展。傳統治療方法往往難以實現長期緩解，而CAR-T細胞療法透過改造患者自身的T細胞使其靶向癌細胞，從而提供更高的療效和更持久的療效。全球癌症發生率的不斷攀升，進一步刺激了對這些先進的個人化治療方法的需求。

進行性或難治性血液腫瘤治療選擇有限，推動了CAR-T細胞療法市場的成長。這些治療方法滿足了亟待解決的關鍵醫療需求，醫護人員和病患對其認知度的提升也促進了其應用。隨著臨床試驗擴展到其他類型的癌症和固態腫瘤，預計需求將進一步成長，CAR-T細胞療法將成為腫瘤學的核心研究方向。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場歷史及展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 產業分析工具
    • 波特五力分析
    • PESTEL 分析

第4章 產品業務分析

  • CAR-T細胞療法市場：產品波動分析
  • Abekuma（Idekabutadiene Vicrucel）
    • Abekuma（Idekabutadiene Viclecel）市場，2021-2033
  • Braiang（溶卡他二烯馬拉色爾）
    • Breyange（Lysocabtadiene Malarocell）市場，2021-2033
  • Calvicti（Siltacaptadiene autoleucel）
    • Calvikti（Siltacaptadiene Autoleucel）市場，2021-2033
  • Kymriah (Tisagenrekresel)
    • Kymriah（Tisagenrekresel）市場，2021-2033
  • Tekartus (Brexcabutagene autreucer)
    • Tekartas（Brexcabutagene autoleucel）市場，2021-2033
  • Yeskarta（Akshikabutagene Sirolsel）
    • Yeskarta（Axiskabutagene Siroluesel）市場，2021-2033
  • 其他
    • 其他市場，2021-2033年

第5章：依疾病指徵進行業務分析

  • CAR-T細胞療法市場：疾病特異性波動分析
  • 白血病
    • 白血病市場，2021-2033年
  • 淋巴瘤
    • 淋巴瘤市場，2021-2033年
  • 多發性骨髓瘤
    • 多發性骨髓瘤市場，2021-2033年
  • 其他
    • 其他市場，2021-2033年

第6章 依最終用途進行業務分析

  • CAR-T細胞療法市場：終端用戶波動分析
  • 醫院
    • 醫院市場，2021-2033年
  • 癌症治療中心
    • 癌症治療中心市場，2021-2033年

第7章 區域業務分析

  • 2025 年和 2033 年 CAR-T 細胞療法的區域市場佔有率
  • 北美洲
    • 2021-2033年北美CAR-T細胞療法市場
    • 美國
    • 加拿大
  • 歐洲
    • 2021-2033年歐洲CAR-T細胞療法市場
    • 英國
    • 德國
  • 亞太地區
    • 2021-2033年亞太地區CAR-T細胞療法市場
    • 日本
    • 中國
  • 世界其他地區
    • 2021-2033年世界其他地區CAR-T細胞療法市場

第8章 競爭情勢

  • 公司分類
  • 策略藍圖
  • Company Position Analysis, 2025
  • 公司簡介/列表
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Gilead Sciences, Inc.
    • Johnson &Johnson Services, Inc.
    • JW Therapeutics（Shanghai）Co., Ltd.
    • bluebird bio, Inc.
    • Merck &Co., Inc.
    • Sangamo Therapeutics
    • Sorrento Therapeutics, Inc.
    • GSK plc.
Product Code: GVR-4-68040-090-4

CAR T-cell Therapy Market Summary

The global CAR T-cell therapy market size was estimated at USD 5.82 billion in 2025 and is projected to reach USD 22.36 billion by 2033, growing at a CAGR of 18.06% from 2026 to 2033. Market growth is driven by rising cancer prevalence, adoption of personalized cell therapies, advances in gene editing, and supportive regulations.

Rising Cancer Burden

The rising prevalence of cancer, especially blood cancers like leukemia, lymphoma, and multiple myeloma, is driving the CAR T-cell therapy industry. Traditional treatments often fail to achieve long-term remission, while CAR T-cell therapies, which engineer a patient's T-cells to target cancer, offer higher efficacy and durable responses. Increasing global cancer incidence is boosting demand for these advanced, personalized treatments.

Limited options for aggressive or treatment-resistant blood cancers support CAR T-cell market growth. These therapies address critical unmet needs, and rising awareness among healthcare professionals and patients is driving adoption. Expanding clinical trials into other cancers and solid tumors is expected to increase demand further, making CAR T-cell therapy a central focus in oncology.

Global CAR T-cell Therapy Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global CAR T-cell therapy market report based on product, disease indication, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Abecma (idecabtagene vicleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Carvykti (ciltacabtagene autoleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Yescarta (axicabtagene ciloleucel)
  • Others
  • Disease Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Cancer Treatment Centers
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
  • Rest of World

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Product Segment
      • 1.1.1.2. Disease Indication Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objective
    • 1.4.1. Objective 1
    • 1.4.2. Objective2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis:
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising cancer burden
      • 3.2.1.2. Personalized treatment advantage
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory complexity
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. CAR T-cell Therapy Market: Product Movement Analysis
  • 4.3. Abecma (idecabtagene vicleucel)
    • 4.3.1. Abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
  • 4.4. Breyanzi (lisocabtagene maraleucel)
    • 4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
  • 4.5. Carvykti (ciltacabtagene autoleucel)
    • 4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • 4.6. Kymriah (tisagenlecleucel)
    • 4.6.1. Kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
  • 4.7. Tecartus (brexucabtagene autoleucel)
    • 4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • 4.8. Yescarta (axicabtagene ciloleucel)
    • 4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Disease Indication Business Analysis

  • 5.1. Disease Indication Segment Dashboard
  • 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
  • 5.3. Leukemia
    • 5.3.1. Leukemia market, 2021 - 2033 (USD Million)
  • 5.4. Lymphoma
    • 5.4.1. Lymphoma market, 2021 - 2033 (USD Million)
  • 5.5. Multiple Myeloma
    • 5.5.1. Multiple myeloma market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. CAR T-cell Therapy Market: End Use Movement Analysis
  • 6.3. Hospitals
    • 6.3.1. Hospitals market, 2021 - 2033 (USD Million)
  • 6.4. Cancer treatment centers
    • 6.4.1. Cancer treatment centers market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
  • 7.2. North America
    • 7.2.1. North America CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. UK CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Germany CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.5. Rest of World
    • 7.5.1. Rest of World CAR T-cell Therapy Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Position Analysis, 2025
  • 8.4. Company Profiles/Listing
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Gilead Sciences, Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Johnson & Johnson Services, Inc.
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. bluebird bio, Inc.
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Merck & Co., Inc.
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Sangamo Therapeutics
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Sorrento Therapeutics, Inc.
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. GSK plc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1. Global CAR T-cell therapy market, by region, 2021 - 2033 (USD Million)
  • Table 2. Global CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 3. Global CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 4. Global CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 5. North America CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 6. North America CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 7. North America CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 8. North America CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 9. U.S. CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 10. U.S. CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 11. U.S. CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 12. Canada CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 13. Canada CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 14. Canada CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 15. Europe CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 17. Europe CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 18. Europe CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 19. UK CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 20. UK CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 21. UK CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 22. Germany CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 23. Germany CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 24. Germany CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 25. Asia Pacific CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 26. Asia Pacific CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 27. Asia Pacific CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 28. Asia Pacific CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 29. Japan CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 30. Japan CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 31. Japan CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 32. China CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 33. China CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 34. China CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
  • Table 35. Rest or World CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
  • Table 36. Rest of World CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
  • Table 37. Rest of World CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
  • Table 38. Rest of World CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 CAR T-cell therapy market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 PESTEL analysis
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 CAR T-cell therapy market: Product outlook & key takeaways
  • Fig. 19 CAR T-cell therapy market: Product movement analysis
  • Fig. 20 Global abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
  • Fig. 21 Global breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
  • Fig. 22 Global carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • Fig. 23 Global kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
  • Fig. 24 Global tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
  • Fig. 25 Global yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
  • Fig. 26 Global others market, 2021 - 2033 (USD Million)
  • Fig. 27 CAR T-cell therapy market: Disease Indication outlook key takeaways
  • Fig. 28 CAR T-cell therapy market: Disease Indication movement analysis
  • Fig. 29 Global leukemia market, 2021 - 2033 (USD Million)
  • Fig. 30 Global lymphoma market, 2021 - 2033 (USD Million)
  • Fig. 31 Global multiple myeloma market, 2021 - 2033 (USD Million)
  • Fig. 32 Global others market, 2021 - 2033 (USD Million)
  • Fig. 33 CAR T-cell therapy market: End Use outlook key takeaways
  • Fig. 34 CAR T-cell therapy market: End Use movement analysis
  • Fig. 35 Global hospitals market, 2021 - 2033 (USD Million)
  • Fig. 36 Global cancer treatment centers market, 2021 - 2033 (USD Million)
  • Fig. 37 Regional outlook
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 US CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Canada CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Japan CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 China CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Rest of World CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)